Your browser does not support JavaScript capabilities, which maybe required to display this page properly.


PDF FormatRequires Adobe Acrobat Reader

Table 10.6a

Immunosuppression Use for Induction, 1999 to 2008

Recipients with Intestine Transplants

  Year of Transplant
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Transplants 73 82 113 107 116 152 178 175 198 185
With Immunosuppression Info 71 80 112 106 116 149 167 169 194 182
Induction Drugs 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 0.0% 1.3% 0.0% 0.9% 1.7% 2.7% 1.8% 0.6% 0.5% 0.0%
OKT3 9.9% 5.0% 6.3% 2.8% 1.7% 1.3% 3.6% 14.2% 17.5% 15.4%
Thymoglobulin 4.2% 0.0% 12.5% 31.1% 45.7% 18.8% 15.6% 18.9% 23.7% 33.5%
Zenapax 49.3% 55.0% 24.1% 12.3% 17.2% 12.8% 13.8% 17.2% 9.8% 8.2%
Simulect 1.4% 12.5% 13.4% 13.2% 1.7% 0.7% 3.0% 3.0% 2.1% 0.5%
Campath 0.0% 0.0% 0.0% 1.9% 8.6% 19.5% 22.2% 21.3% 13.4% 18.1%
No Induction Drugs Recorded 39.4% 31.3% 43.8% 39.6% 25.0% 45.6% 45.5% 40.8% 51.0% 40.1%


Source: OPTN/SRTR Data as of May 4, 2009.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.



PDF FormatRequires Adobe Acrobat Reader